• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
        • CR Kids
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Shop
        • CR Media platforms
        • Electronic Edition
        • Subscribe
  • Advertising
  • Kids
  • News Tips
  • Radio/Podcasts
        • Catholic Review Radio
        • Protagonistas de Fe
        • In God’s Image
        • “In Charity and Truth” with Archbishop William E. Lori
  • Subscribe
Mifepristone, the first medication in a chemical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Ill., April 20, 2023. The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug's availability. (OSV News photo/Evelyn Hockstein)

Supreme Court is asked to weigh in on future of abortion pill

September 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, Supreme Court, World News

WASHINGTON (OSV News) — The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower-court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug’s availability.

A coalition of pro-life opponents of mifepristone, the first of two drugs used in a medication or chemical abortion, previously filed suit in an effort to revoke the U.S. Food and Drug Administration’s approval of the drug, arguing the government violated its own safety standards when it first approved the drug in 2000.

However, proponents argued mifepristone poses statistically little risk to women using it for abortion early in pregnancy and claim the drug is being singled out for political reasons.

In its filing on behalf of the FDA, the Justice Department called the appeals court ruling an “unprecedented decision,” arguing its logic “would threaten to severely disrupt the pharmaceutical industry and prevent FDA from fulfilling its statutory responsibilities according to its scientific judgment.”

The filing argued the drug is safe and that “study after study” has shown “serious adverse events are exceedingly rare” when mifepristone is taken under the approved conditions. The filing added, “For many patients, mifepristone is the best method to lawfully terminate their early pregnancies.”

It stated that revoking approval of the pill “would be damaging for women and health care providers around the Nation.”

But in a statement, Erik Baptist, senior counsel for Alliance Defending Freedom, which is representing the pro-life coalition challenging mifepristone’s approval, said the FDA “has been entrusted to serve as the nation’s gatekeeper of legal drugs.”

“By repeatedly and unlawfully removing critical safeguards in the chemical abortion regimen, the FDA has failed to protect the safety of women and girls,” he said. “Two courts have now held the FDA accountable for the damage it has done to the rule of law and the harm it has caused to countless girls and women. We hope the Supreme Court does the same.”

Earlier this year, the Supreme Court blocked a lower court’s restrictions on mifepristone, leaving the abortion pill on the market while litigation proceeds. That decision froze the lower court’s ruling to stay the FDA’s approval of the drug.

The Justice Department and Danco, the pharmaceutical company that manufactures mifepristone, previously asked the Supreme Court to intervene in the case after an appeals court allowed portions of the ruling by U.S. District Judge Matthew Kacsmaryk to take effect.

In a Sept. 8 statement, Danco said it “continues to be at the forefront of this fight and is working closely with the reproductive rights community and pharmaceutical industry to support the changes made by FDA.”

Should the Supreme Court take the case, it would likely be added to its docket in its coming term.

The two-drug chemical abortion regimen is currently legal in some form in 36 states and the District of Columbia. It is permitted in 21 states, but with some additional restrictions in the remaining 15, according to data from the Guttmacher Institute, which supports abortion access.

The Catholic Church opposes abortion, teaching that all human life is sacred from conception to natural death and that society must extend support to mothers and children. Earlier this year, Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, denounced Biden administration’s attempts to loosen regulations around the abortion bill, saying the U.S. bishops “decry the continuing push for the destruction of innocent human lives and the loosening of vital safety standards for vulnerable women.”

A link to the Justice Department’s filing is here: https://s3.documentcloud.org/documents/23945337/usfda-et-al-v-alliance-for-hippocratic-medicine-et-al-petition.pdf.

Read More Respect Life

Inside Baltimore’s fight against human trafficking

Entrepreneur uses tech to combat human trafficking

Catholics make the case for care over assisted suicide

NY archbishop, archdiocese, healthcare ministry join in suit over state’s assisted suicide law

Appeals court rules Idaho abortion ban may be enforced as voters prepare to weigh in

Serving vulnerable pregnant and parenting women is ‘heroic’ work, says USCCB pro-life chair

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Archbishop Lori announces appointments of vicar for clergy, vocations director, pastors, vicars forane 
  • Archbishop Lori brings message of hope, redemption to Maryland inmates
  • Inside Baltimore’s fight against human trafficking
  • University of Maryland Medical System breaks ground on new outpatient care enter 
  • Entrepreneur uses tech to combat human trafficking

| Latest Local News |

Lawyer honored by St. Thomas More Society of Maryland sees hand of God in fight for religious liberty

Inside Baltimore’s fight against human trafficking

Entrepreneur uses tech to combat human trafficking

Catholics make the case for care over assisted suicide

Office of Black Catholic Ministries to host upcoming mental health retreat 

| Latest World News |

Pope Leo XIV departs for 12 day tour of South America

Pope Leo heads to a divided Argentina still reckoning with Francis’ legacy

At Peruvian shrine, Pope Leo will return to the missionary model that shaped him

Vatican: Pope Leo ‘enthusiastic’ and ‘clinically fit’ for whirlwind Latin America homecoming

Democrats win control of House and Senate in landslide midterm election seen as Trump rebuke

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Lawyer honored by St. Thomas More Society of Maryland sees hand of God in fight for religious liberty
  • Pope Leo XIV departs for 12 day tour of South America
  • The day I achieved my Mass attendance goal (and kept going)
  • Pope Leo heads to a divided Argentina still reckoning with Francis’ legacy
  • Inside Baltimore’s fight against human trafficking
  • Traveler, there is no road
  • Entrepreneur uses tech to combat human trafficking
  • At Peruvian shrine, Pope Leo will return to the missionary model that shaped him
  • Vatican: Pope Leo ‘enthusiastic’ and ‘clinically fit’ for whirlwind Latin America homecoming

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED